Emerging therapeutic targets for synovial sarcoma.

Stefano Ferrari, Emanuela Palmerini, Anna Paioli

Journal: Expert review of anticancer therapy 2016;14(7):791-806

PMID: 24661286

Abstract

Synovial sarcoma is part of soft tissue sarcomas, an uncommon group of malignant tumors of mesenchymal origin. Unfortunately, a very limited number of useful drugs are active for most advanced synovial sarcoma. These tumors showed VEGF expression, and elevated serum VEGF levels correlate with higher histologic tumor grade. Inhibition of VEGFR was associated with tumor activity in preclinical models of synovial sarcoma and drugs such as sorafenib, pazopanib and bevacizumab have been employed in synovial sarcoma in monotherapy and in combination with chemotherapy. Other targets such as EGFR, HER2, IGFR-1R and mTOR have been exploited, but their inhibition by drugs such as gefitinib, trastuzumab, figitumumab, and temsirolimus, has not resulted in meaningful activity. Newer approaches include CXCR4 inhibition, immune-based therapies (NY-ESO-1), targeting epigenetic misregulation with HDAC inhibitors and targeting developmental pathways such Notch and Hedgehog. This review will summarize achievements and pitfalls of drugs against emerging therapeutic targets for synovial sarcoma.

Address: Chemotherapy, Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy.

DOI: 10.1586/14737140.2014.901155

Link outs

Free resources

Other Literature Sources:

https://scite.ai/reports/24661286

Miscellaneous:

https://assays.cancer.gov/CPTAC-802

Research Materials:

https://antibodies.cancer.gov/detail/CPTC-EGFR-8

Subscription / membership required

Full Text Sources:

MeSH Terms: Antibodies, Monoclonal, Antineoplastic Agents, Bevacizumab, Everolimus, Humans, Indazoles, Indoles, Molecular Targeted Therapy, Niacinamide, Phenylurea Compounds, Pyrimidines, Pyrroles, Receptors, Vascular Endothelial Growth Factor, Sarcoma, Sarcoma, Synovial, Sirolimus, Sorafenib, Sulfonamides, Sunitinib, TOR Serine-Threonine Kinases